REFERENCES
- Briseid K, Hoem NO, Johannesen S, Vangen AM, Westgaard T. Significance of IgG for the activity of factor XII measured in human plasma. Scand J Clin Lab Invest 1996; 56: 725 — 34.
- Pixley RA, De La Cadena R, Page JD, Kaufman N, Wyshock EG, Chang A, Taylor Jr FB, Colman RW. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti- factor XII antibody to block contact activation in baboons. J Clin Invest 1993; 91: 61 — 8.
- Pixley RA, Stumpo LG, Birkmeyer K, Silver L, Colman RW. A monoclonal antibody recognizing an icosapeptide sequence in the heavy chain of human factor XII inhibits surface-catalyzed activa-tion. J Biol Chem 1987; 262: 10140 — 5.
- Hojima Y, Pierce JV, Pisano JJ. Hageman factor fragment inhibitor in corn seeds: purification and characterization. Thromb Res 1980; 20: 149 — 62.
- Chong GL, Reeck GR. Interaction of trypsin, factor XIIa, and plasma kallikrein with a trypsin inhibitor isolated from barley seeds: a comparison with the corn inhibitor of activated Hageman fac-tor. Thromb Res 1987; 48: 211 — 21.
- Veloso D, Silver LD, Hahn S, Colman RW. A monoclonal anti-human plasma prekallikrein antibody that inhibits activation of prekallikrein by factor XIIa on a surface. Blood 1987; 70: 1053— 62.
- Veloso D, Colman RW. Western blot analyses of prekallikrein and its activation products in human plasma. Thromb Haemost 1991; 65: 382 — 8.
- Veloso D, Smith JI, Denny S, Cosgriff TM. Structure, kinetics, and function of human and rhesus plasma prekallikreins are similar. Thromb Hae-most 1992; 68: 526 — 33.
- Laake K, Vennerod AM. Determination of factor XII in human plasma with arginine protesterase (prekallikrein). I. Preparation and properties of the substrate. Thromb Res 1973; 2: 394 —407.
- Hoem NO, Johannesen S, Hauge G, Rud AC, Sandem S, Briseid K. Contact activation factors in plasma from women using oral contraceptives. Increased levels of factor XII, kinin-free high mole-cular weight kininogen and acetone-activated kallikrein. Thromb Res 1991; 64: 427 —34.
- Fossum S, Hoem NO, Johannesen S, Korpberget M, Nylund E, Sandem S, Briseid K. Contact fac-tors in plasma from women on oral contracep-tion—significance of factor XI for the measured activity of factor XII. Thromb Res 1994; 74: 477 — 85.
- Nagase H, Barrett AJ. Human plasma kallikrein. A rapid purification method with high yield. Biochem J 1981; 193: 187–92.
- Mancini G, Carbonara AO, Heremans JF. Immu-nochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 1965; 2: 235 — 54.
- Briseid K, Hoem NO, Johannesen S, Marthinsen K. Functional correlation between kallikrein and factor XII activated in human plasma. Thromb Res 1990; 57: 945 —56.
- Hoem NO, Johannesen S, Briseid K. Formation of an association between factor XII and kallikrein in human plasma—significance of storage of plasma and the functional state of plasma kallikrein. Thromb Res 1992; 66: 421 — 34.
- Briseid K, Hoem NO, Johannesen S, Haug K. Amidolytic assay of factor XI in human plasma—significance of kallikrein for the activity measured. Thromb Res 1995; 78: 239 — 50.
- Tans G, Janssen-Claessen T, Rosing J, Griffin JH. vStudies on the effect of serine protease inhibitors on activated contact factors. Application in amidolytic assays for factor XIIa, plasma kallikrein and factor XIa. Eur J Biochem 1987; 164: 637–42.
- Kluft C. Determination of prekallikrein in human plasma: optimal conditions for activating prekal-likrein. J Lab Clin Med 1978; 91: 83 — 95.
- Friberger P, Eriksson E, Gustavsson S, Claesson G. Determination of prekallikrein in plasma by means of a chromogenic tripeptide substrate for plasma kallikrein. In: Fujii S, Moriya H, Suzuki T, editors. Advances in experimental medicine and biology. Kinins II. New York: Plenum Press, 1979; 120A: pp. 67 — 82.
- Ito R, Statland BE. Centrifugal analysis for plasma kallikrein activity, with use of the chromogenic substrate S-2302. ClinChem 1981; 27: 586–93.